Deliatroph Pharmaceuticals Inc entered the industry of Medical Research in 1998 and has grown to employ 1 to 4 people, generating an annual revenue of $500.000 to $999.999. The NAICS classifies this business under the code 541720, which describes it as a Medical Research. For further clarification, the SIC classifies this business under the code 8733 and described it as a Medical Research. The business provides service to the B2B market.
To acquire more information, please contact Per Borgstrom by calling (858) 459-1799 during business hours. You can also write to the business’ Single Location at 2325 Camino Del Collado, La Jolla, California CA 92037. You can also visit the company’s website at . View this business’ social media profiles on Twitter or on Facebbok .
| Company: | Deliatroph Pharmaceuticals Inc |
| Representative: | Per Borgstrom |
| Place of Business: | 2325 Camino Del Collado, La Jolla, CA 92037 |
| Contact Number: | (858) 459-1799 |
| Type of Service: | Medical Research |
| SIC Number: | 8733 |
| NAICS Number: | 541720 |
| Locality: | Single Location |
| Market Type: | B2B (Business to Business) |
| Began: | 1998 |
| Income/Year: | $500.000 to $999.999 |
| Laborers: | 1 to 4 |
| Share This Company: |
Deliatroph Pharmaceuticals Inc is a company operating from San Diego, California providing professional Medical Research and relevant B2B variables. It was founded in 1998 and registered with the SIC code 8733 as Medical Research, and with the NAICS code 541720 as Medical Research.
With a current employee count of 1 to 4, Deliatroph Pharmaceuticals Inc has gone to report making $500.000 to $999.999 per annum on its journey towards growth. This company invites you to contact its representative Per Borgstrom at (858) 459-1799 for related queries, or to locate its Single Location using the coordinates 32.86154,-117.253209.
The Single Location can also be found at the street address 2325 Camino Del Collado in La Jolla, California 92037 and can be engaged online through the company website at , the company Twitter , and Facebook page .